Navigation Links
TGen President Dr. Jeffrey Trent speaks at Brookings Institution biomedical conference
Date:7/15/2013

WASHINGTON, D.C. July 15, 2013 Dr. Jeffrey Trent, President and Research Director for the Translational Genomics Research Institute (TGen), will discuss state-of-the-art genomics research July 16 at the Brookings Institution.

Dr. Trent, Ph.D., F.A.C.M.G., and former Scientific Director of the National Human Genome Research Institute, is part of a panel, Innovation in Action, at Brookings' 2nd annual State of Biomedical Innovation Conference, which will focus on the use of novel data sources to improve medical product development and care delivery.

Specifically, Dr. Trent will discuss TGen's ongoing work in translating genomics research into clinical benefit. TGen is one of a very few centers who are using the entire human genome in clinical trials in order to diagnose or make treatment decisions for an individual patient (precision medicine).

"The human genome will be the medical textbook for the next century and beyond," Dr. Trent said. "By harnessing the power of the human genome, we will provide immeasurable patient benefit while at the same time reducing the time and costs of diagnosis and treatment. TGen is a global leader in clinical trials that deploy this form of innovative research."

TGen's translational model enables pioneering discoveries in the laboratory to be quickly moved to clinical trials where they can be used to immediately benefit patients with many types of cancer and other debilitating diseases.

Dr. Trent's panel will be moderated by Dr. Mark B. McClellan, Director and Fellow of Brookings' Initiative on Innovation and Value in Health Care. He is the former administrator for the Centers for Medicare and Medicaid Services (2004-2006), and the former commissioner of the Food and Drug Administration (2002-2004). He also served as a member of the President's Council of Economic Advisers, and as senior director for health care policy at the White House (2001-2002). In these positions, he develop
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. BioNano Genomics Appoints Dr. Fahim Amini As Vice President Commercial Operations EMEA
2. Homeland Security Corporation (HSCC) Appoints New President with Biometrics and Access Control Solutions Expertise and Contacts
3. Statement by WCS president and CEO on historic CITES ruling
4. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
5. Bluemetal Architects appoints David Le Penske as Vice President of Health & Life Sciences
6. President Obama honors MU researcher with National Medal of Science
7. ONR-funded young innovators recognized by President
8. NASA Goddard scientist receives Presidential Early Career Award
9. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
10. UCLAs Yi Tang receives Presidential Green Chemistry Challenge Award from EPA
11. President, CEO Leppävuori, VTT: Finland should create a national bioeconomy strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
(Date:7/24/2014)... Einstein College of Medicine of Yeshiva University have ... for Parkinson,s Research to translate a basic science finding ... project will test chemical compounds on a newly identified ... acts on an underlying cause of the disease. ... manage their symptoms, we are eager to stop or ...
(Date:7/24/2014)... Forest is a hotspot of biodiversity and one of ... and toads) in the world. However, current levels of ... years has been an increase in the description of ... advance of molecular techniques and availability of samples for ... of samples for molecular and morphological analysis, researchers from ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3A tiny new species of frog from Brazil with a heroic name 2
... , This release is available in German ... now be produced inexpensively and in large quantities. This means ... 225 million malaria patients in developing countries at an affordable ... Interfaces in Potsdam and the Freie Universitt Berlin have developed ...
... Can a one-size-fits all approach really work? The world ... In the west it is already widespread and it ... change in the lifestyles of recent generations., "Fat, Fate and ... tackled by focusing solely on adult lifestyles and asks the ...
... evolve the ability to grow beyond the tissues in ... tumor cells -- are tethered to scaffolding that helps ... University of Helsinki, Finland, and from UCSF have identified ... them to further misbehave. The protein, they ...
Cached Biology News:Anti-malaria drug synthesized with the help of oxygen and light 2Anti-malaria drug synthesized with the help of oxygen and light 3'Fat, Fate and Disease' 2Some breast cancer spread may be triggered by a protein, study shows 2Some breast cancer spread may be triggered by a protein, study shows 3
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... , July 24, 2014 Lyfebulb, ... Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First North ... or "the Company"), announced a collaboration to increase ... last night at an event attended by more ... parties. Lyfebulb is a health and wellness company ...
(Date:7/23/2014)... Inc. (NASDAQ: SGMO ) today reported its ... For the second quarter ended June 30, 2014, ... or $0.10 per share, compared to a net loss ... same period in 2013. As of June 30, 2014, ... interest receivable of $236.7 million. Revenues for ...
Breaking Biology Technology:Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... Each year, thousands of Amgen staff generously devote their ... charitable organizations. To recognize these exceptional efforts, the Amgen Foundation ... Excellence in Volunteering Awards. The Awards ... Rico who are making a difference in the communities ...
... 2011 Generex Biotechnology Corporation ( www.generex.com ) ... status of the previously announced spinout of its ... The Company is in the midst ... transaction opportunities, including both shell companies and operating ...
... 2011 EvaluatePharma Ltd, the research company, is ...  With a team based in Tokyo, EvaluatePharma Japan KK will ... Japan. "Japan is a very important market for ... major customers from a distance, but it is now time ...
Cached Biology Technology:Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 2Amgen Staff Volunteer Efforts Result in $5,000 For Each of Their Favorite Nonprofits 3Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4EvaluatePharma Japan KK - Now Open for Business in Tokyo 2
Immulon 2HB, Flat Bottom, 50/Bx; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
Black 96 Well Plate EB, RE Bottom...
...
...
Biology Products: